findmyKOL

Hope Rugo, MD

Enriched profile

Director, Women's Cancers Program; Division Chief, Breast Medical Oncology; Professor, Department of Medical Oncology & Therapeutics Research · City of Hope

ORCIDNPI
Region🇺🇸 San Francisco, CA · West · United StatesSpecialtyHematologyFocusAdvanced Breast Cancer Therapies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2004–2023

Hope Rugo is Director, Women's Cancers Program; Division Chief, Breast Medical Oncology; Professor, Department of Medical Oncology & Therapeutics Research at City of Hope. OpenAlex indexes 1,607 publications with 103,502 citations (h-index 140); ClinicalTrials.gov lists 30 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Hope Rugo, MD, is Director, Women's Cancers Program at City of Hope (Beckman Research Institute / City of Hope Comprehensive Cancer Center, Duarte, CA). The public record shows 1,607 publications with 103,502 citations (h-index 140), centered on Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research. It also documents an investigator role on 30 registered clinical trials, industry payments reported by 34 companies, 2 NIH-funded awards (2004–2023).

  • Most recent indexed publication: 2026 · Cardio-oncology (London, England)
  • Top research focus: Advanced Breast Cancer Therapies
  • 30 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 34 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer30 trialsNeoplasm Metastasis2 trialsFatigue1 trialSarcoma1 trialComa1 trialHemangiosarcoma1 trialBrain Neoplasms1 trialParesthesia1 trial

Research focus

OpenAlex concept fingerprint
Advanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Ibrancegeneric · PalbociclibClinical trials2Industry payments53Publications13Enhertugeneric · TrastuzumabClinical trials3Industry payments40Publications13Orserdugeneric · ElacestrantClinical trials1Industry payments16Publications1

Works with

trial sponsors and companies reporting payments
Stemline Therapeutics, Inc.Clinical trials1Industry payments19Eli Lilly and CompanyClinical trials2Industry payments6Gilead Sciences, Inc.Clinical trialsIndustry payments109

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,607publications

Distinct works indexed by OpenAlex, matched via ORCID; 109 in PubMed.

103,502citations

Total citations across indexed works.

140h-index

Hirsch index (OpenAlex). i10-index 613.

Clinical & industry

trials, payments and federal funding
30clinical trials

Investigator role on registered studies.

View trials
34companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2004–2023

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 30 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

34 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    63.2%
    Aromatase Inhibitor40.7%
    Letrozole72%Exemestane17%Anastrozole10%
    Part D<11 patients
    Kinase inhibitor12.1%
    Kisqali100%
    Part D<11 patients
  • Nervous system

    23.3%
    Atypical Antipsychotic9%
    Olanzapine100%
    Part D<11 patients
    Gabapentinoids7%
    Gabapentin100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    6.5%
    Serotonin-3 Receptor Antagonist6.5%
    Ondansetron Hcl100%
    Part D11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20042023 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/hope-rugo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • X / Twitter

    x.com/hoperugo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/p/DP8dyRiAHrc

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com
  • LinkedIn

    linkedin.com/posts/city-of-hope_dr-hope-s-rugo-breast-cancer-awareness-activity-7382165654159769600-0HNE

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • LinkedIn

    linkedin.com/posts/city-of-hope_we-are-excited-to-share-hope-s-rugo-md-activity-7318309503492382721--_Hs

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellow

    American Society of Clinical Oncology (FASCO)

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org
  • Postdoctoral Fellowship

    Immunology, Stanford University

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • M.D.

    University of Pennsylvania School of Medicine

    1984
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • B.S. in Chemistry

    Tufts University

    1979
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org
  • Residency

    Internal Medicine and Primary Care, UCSF

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • Fellowship

    Hematology and Oncology, UCSF

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu

Editorial & leadership roles

journal and society appointments
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org
  • Co-Chair

    Triple Negative Working Group, Translational Breast Cancer Research Consortium (TBCRC)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →anixa.com
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Professor Emeritus

    Medicine, UCSF School of Medicine

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • Member

    Breast Cancer Clinical Advisory Board, Anixa Biosciences, Inc.

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →anixa.com
  • Investigator

    Breast Cancer Research Foundation (BCRF)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org
2 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
4 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.